PMOS Starts With Insulin Resistance. DEE ZYR Addresses It — With Four Ingredients Whose Evidence Is Backed by Published Indian Clinical Research.

Myo-Inositol 1.1g

Insulin Sensitisation · Oocyte Quality · Ovulation

Myo-Inositol (MI) is the most abundant inositol isomer in the human body and serves as the precursor to inositol-containing phospholipids that act as second messengers in the insulin signalling cascade. In PMOS, deficiency of Myo-Inositol in ovarian cells impairs this signalling, contributing to both insulin resistance and poor follicular development. Supplementation with Myo-Inositol restores ovarian insulin sensitivity, improves FSH receptor signalling and enhances oocyte energy metabolism. Clinical evidence shows that MI supplementation restores spontaneous ovulation in women with PMOS-related anovulation, reduces insulin levels, lowers free testosterone and improves oocyte quality in women undergoing IVF. The 40:1 ratio of Myo-Inositol to D-Chiro-Inositol — reflected in DEE ZYR’s 1.1g MI to 27.6mg DCI composition — is supported as the physiologically optimal ratio for ovarian function.

D-Chiro-Inositol 27.6mg

Androgen Reduction · Glycogen Synthesis · Peripheral Insulin Sensitivity

D-Chiro-Inositol (DCI) acts as a second messenger in the post-receptor insulin signalling pathway, specifically promoting glycogen synthesis in peripheral tissues and reducing hyperinsulinaemia by improving cellular glucose uptake. In the ovary, DCI-based second messengers stimulate aromatase activity — which converts androgens to oestrogen — while simultaneously reducing androgen production at the theca cell level. The net result is a meaningful reduction in circulating androgens, which translates clinically to reduced hirsutism, improved acne and better menstrual regularity. At 27.6mg, DCI in DEE ZYR is precisely at the 40:1 ratio with MI — the formulation supported by multiple clinical studies as optimal for balancing ovarian and peripheral insulin effects without over-suppressing follicular activity.

L-Methylfolate 1.0mg

Active Folate · DNA Integrity · Neural Tube Protection · MTHFR Support

L-Methylfolate is the biologically active form of folate — the form that the body can use directly, without requiring MTHFR enzyme conversion. Standard folic acid must be converted to L-Methylfolate in the body before it can participate in folate-dependent biochemical reactions, including DNA synthesis, cell division and the methylation cycle. Up to 40% of Indians carry MTHFR gene variants that impair this conversion — making standard folic acid supplementation ineffective in a substantial proportion of women. L-Methylfolate bypasses this bottleneck entirely. For women with PMOS who may be planning pregnancy, DEE ZYR’s 1.0mg of L-Methylfolate provides the active folate needed for oocyte development, reduces homocysteine (elevated in many PMOS patients) and protects against neural tube defects in early pregnancy.

Vitamin D3 1000 IU

Insulin Sensitivity · Ovarian Function · Hormonal Balance

Vitamin D3 deficiency is exceptionally prevalent in India — affecting an estimated 70–90% of the general population — and is disproportionately common in women with PMOS. This is not a coincidence. Vitamin D3 receptors are present on ovarian cells, and Vitamin D3 plays an active role in regulating insulin sensitivity, AMH signalling, follicular development and the conversion of androgens to oestrogen. Low Vitamin D3 independently worsens insulin resistance and is associated with more severe PMOS presentations. Supplementation with 1000 IU/day — as in DEE ZYR — corrects mild-to-moderate deficiency in most Indian women, improving both metabolic parameters and reproductive outcomes when combined with the inositol components.